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Background & objectives: Information available on HIV-2 and dual infection (HIV-1/2) is limited. This 
study was carried out among HIV positive individuals in an urban referral clinic in Khar, Mumbai, India, 
to report on relative proportions of HIV-1, HIV-2 and HIV-1/2 and baseline characteristics, response to 
and outcomes on antiretroviral treatment (ART).
Methods: Retrospective analysis of programme data (May 2006-May 2009) at Khar HIV/AIDS clinic at 
Mumbai, India was done. Three test algorithm was used to diagnose HIV-1 and -2 infection. Standard 
ART was given to infected individuals. Information was collected on standardized forms.
Results: A total of 524 individuals (male=51%; median age=37 yr) were included in the analysis over a 
3 year period (2006-2009) - 489 (93%) with HIV-1, 28 (6%) with HIV-2 and 7(1%) with dual HIV-1/2 
infection. HIV-2 individuals were significantly older than HIV-1 individuals (P<0.001). A significantly 
higher  proportion  of  HIV-2  patients  and  those  with  dual  infections  had  CD4  counts  <200  cells/µl 
compared to HIV-1. HIV-2 individuals were more likely to present in WHO Clinical Stage 4. Of the 443 
patients who were started on ART, 358 (81%) were still alive and on ART, 38 (8.5%) died and 3 were 
transferred out. CD4 count recovery at 6 and 12 months was satisfactory for HIV-1 and HIV-2 patients 
on protease inhibitor based regimens while this was significantly lower in HIV-2 individuals receiving 3 
nucleoside reverse transcriptase inhibitors.
Interpretation & conclusions: In an urban HIV clinic in Mumbai, India, HIV-2 and dual infections are 
not uncommon. Adaptation of the current national diagnostic and management protocols to include 
discriminatory testing for HIV types and providing access to appropriate and effective ART regimens 
will prevent the development of viral resistance and preserve future therapeutic options.
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683  HIV type I (HIV-1) and type 2 (HIV-2) are very 
closely  related  but  differ  in  pathogenicity,  natural 
history and therapy. HIV-1 is more easily transmitted 
and  consequently  accounts  for  the  vast  majority  of 
global HIV infections. The less transmissible HIV-2 
was	 thought	 to	 be	 largely	 confined	 to	 West	 Africa	
(where it is thought to have originated)1,2 but has spread 
to parts of Europe and India3-5.
  When  compared  to  HIV-1,  HIV-2  infected 
individuals have a much longer asymptomatic stage, 
slower progression to AIDS6-8, slower decline in CD4 
count6,9,10 lower  mortality7,11 ,  lower  rate  of  vertical 
transmission12-14  and  smaller  gains  in  CD4  count  in 
response to antiretroviral treatment (ART)15-17.
  Serologic  reactivity  to  HIV-1  and  HIV-2  (HIV-
1/2) has also increased in HIV-2 endemic areas over 
the  past  decade18,19. In  terms  of  antiretroviral  drug 
regimens,  HIV-2  is  intrinsically  resistant  to  non 
nuclesoside reverse transcriptase inhibitors (NNRTI) 
such as nevirapine and efavirenz and not all the protease 
inhibitors (PIs) provide good viral suppression15.
  Since the introduction of ART, several published 
papers  (particularly  from  Africa)  have  described 
the  clinical  characteristics,  response  and  treatment 
outcomes of HIV-1 infected patients on ART19-22. In 
contrast,  there  is  a  dearth  of  published  information 
on HIV-223-24 (and dual HIV-1/2). Information on the 
distribution  of  HIV-2  and  dual  infection  across  the 
Indian subcontinent is limited and current surveillance 
by  the  National  Programme  does  not  pick  up  this 
information24. The current national guidelines and the 
diagnostic and treatment algorithms do not allow for 
discrimination in the diagnosis of HIV infection by 
type or provide for treatment alternatives for HIV 2 and 
dual infected persons. From a public health perspective, 
it is important to assess the characteristics as well as 
response to ART for HIV-2 and dual infections.
  We  therefore  carried  out  a  study  among  HIV 
positive  individuals  in  an  urban  referral  clinic  in 
Mumbai,  India  to  report  on  relative  proportions  of 
HIV-1, HIV-2 and HIV-1/2, and baseline characteristics, 
response to and outcomes on ART.
Material & Methods
Study setting and population: This retrospective study 
was done between May 2006 and May 2009 at Khar 
HIV/AIDS clinic in Mumbai, Maharashtra State, India. 
This clinic is managed by Médecins Sans Frontières 
(MSF).
  MSF started an HIV project in Mumbai in February 
2006  in  collaboration  with  the  Mumbai  district 
authorities to provide access to populations who did 
not have access to the public system namely: HIV2, 
HIV-TB  co-infection,  Hepatitis  B  co-infection  and 
drug resistant tuberculosis.
  HIV positive patients diagnosed elsewhere are also 
referred to the MSF clinic where a discriminatory HIV-
test is offered free-of charge to identify the type of HIV 
infection. HIV testing involves a three test algorithm. 
This  includes  Microparticle  Enzyme  Immunoassay 
(ABBOTT-AxSYM,  Mumbai,  India),  Enzyme 
Immunoassay  (MICROELISA-J  Mitra,  Mumbai, 
India)  and  Rapid  Immunochromatography  (TriDot, 
Mumbai, India). Tridot discriminates between HIV-1 
and	HIV-2.	Confirmatory	Western	blot	is	done	in	the	
MSF Clinic for all the samples positive for HIV-2 or 
-1 and 2. All HIV-positive individuals undergo a full 
clinical and immunological assessment. 
  The  study  population  for  determining  relative 
proportions  of  HIV  types  included  all  consecutive 
people living with HIV (PLHA) registered in the MSF 
clinic, while response to ART and treatment outcomes 
were  assessed  among  all  consecutive  patients  who 
started ART. The Khar clinic is open to all patients in 
Mumbai irrespective of geographical residence.
Antiretroviral therapy: Apart from pregnant women, 
HIV-positive  individuals  were  eligible  for  ART  if 
they presented in WHO Clinical Stage 3 (with CD4 
count equal or less than 350 cells/µl), WHO stage 4 
irrespective of CD4 count or have a CD4-lymphocyte 
count  <200  cells/µl  (irrespective  of  WHO  stage2,5. 
HIV-infected pregnant women were initiated on ART 
when	 their	 CD4-lymphocyte	 count	 was	 ≤350	 cells/
µl, regardless of clinical stage. Once started on ART 
patients were reviewed by a clinician 2 wk later and 
monthly thereafter. Individuals who started ART had 
their WHO clinical stage, CD4 cell count and weight 
measured at baseline and then at 6 monthly intervals.
	 For	 HIV-1,	 first-line	 ART	 was	 a	 fixed	 dose	
combination of stavudine (d4T) or zidovudine (AZT), 
lamuvudine (3TC) and nevirapine (NVP) or efavirenz 
(EFV). In case of double toxicity to zidovudine (AZT) 
and stavudine (d4T), the alternative treatment is tenofovir 
(TDF). In the event of renal failure (creatinine clearance 
<50) tenofovir (TDF) was replaced with abacavir (ABC).
	 For	HIV-2,	first-line	ART	was	selected	according	to	
the background (previous history of intake) of ART. For 
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ART naïve patients, 3 nucloside reverse transcriptase 
inhibitors	(NRTIs)	were	given:	TDF	and	a	fixed	dose	
combination  of  zidovudine  (AZT)  and  lamivudine 
(3TC). In case of renal failure, TDF was replaced with 
ABC. 
  For ART experienced patients, a PI based regimen 
was given which included indinavir (IDV), ritonavir 
(RTV)	and	fixed	dose	combination	of	stavudine	(d4T)	
and lamuvudine (3TC). Boosted indinavir was preferred 
to  lopinavir/ritonavir  for  HIV-2  infection  based 
on  previous  information15,26-29.  Lopinavir/ritonavir 
(LPV/r) was given only in case of severe intolerance 
to IDV.	For	HIV-2	and	HIV-1&2	co-infection,	the	first	
line	treatment	was	a	fixed	dose	combination	of	d4T	
and 3TC plus lopinavir/ritonavir (LPV/r), in the heat 
stable form. Lopinavir/ritonavir (LPV/r) in this case is 
preferred to indinavir because the disease is driven by 
HIV-1 infection.
Data  collection  and  treatment  outcomes:  Structured 
forms were used to gather information on HIV status, 
HIV-type, WHO clinical stage and CD4 cell count at 
presentation. ART treatment outcomes were recorded 
on a monthly basis from Treatment cards. Data were 
entered and stored in the FUCHIA database system 
(FUCHIA, Epicentre, Paris, France). Data were collated 
on all patients from May 2006 and were censored at the 
end of June 2009. 
  Standardised  treatment  outcomes  were  monitored 
on	a	monthly	basis	and	were	defined	as:	alive	and	on	
ART (patient alive and on ART at the facility where 
he/she was registered); died (patient who had died for 
any reason while on ART), lost to follow up (patient 
who did not attend the clinic for one month or more 
after their scheduled follow up appointment); stopped 
treatment (patient known to have stopped treatment for 
any reason during treatment); transferred out (patient 
who  had  transferred-out  permanently  to  another 
treatment facility). 
Statistical  analysis:  Previous  reports  from  India3,4 
have showed a HIV-2 prevalence of about 5 per cent. 
Assuming that the same proportion is applicable to our 
setting and the worst possible result that we would like 
to	detect	is	7	with	a	95	per	cent	confidence	interval	
and 2 per cent error, a total of at least 456 consecutive 
individuals was required. 
  Differences between groups were compared using 
the χ² test for categorical variables and the Wilcoxon 
rank-sum test for continuous variables. The level of 
significance	was	set	at	 P<0.05.  Data  were  analysed 
using the STATA/IC 10.0 software (Stata corporation, 
Texas 77845, USA). 
  This  study  received  ethical  clearance  from  the 
ethics review committees of the international Union 
Against  TB  and  Lung  disease  and  Médecins  Sans 
Frontières. 
Results
Cohort  characteristics:  A  total  of  611  individuals 
tested HIV-positive, of whom 87 did not have HIV-
type	 specified	 and	 were	 therefore,	 excluded	 from	
the analysis. Among the remaining 524 individuals 
included in the study, 272 (52%) were male, (median 
age 37 yr, range: 2-65 yr). Nearly half (43%) reported 
earning a regular income, 96 (18%) were housewives, 
33 (6%) were sex workers, 12 (2%) were students, 
3  (1%)  were  businessmen  and  156  (30%)  were 
unemployed (Table I). 
  There were 489 (93%) individuals with HIV-1, 28 
(6%) with HIV-2 and 7 (1%) with dual HIV-1/2 infection. 
HIV-2	individuals	were	significantly	older	(>	45	yr)	
than	HIV	individuals.	A	significantly	higher	proportion	
of HIV-2 patients and those with dual infections had 
CD4 counts <200 cells/µl compared to HIV-1. Among 
HIV-1, HIV-2 and HIV-1/ 2 infections, 414 (85%), 25 
(89%) and 4 (57%) started ART respectively.
Characteristics of patients on ART and immunologic 
outcomes: Among  the  524  HIV-positive  individuals 
with	HIV-type	classified,	443	started	ART.	Of	these,	
414  (93%)  had  HIV-1,  25  (6%)  had  HIV-2  and  4 
(1%), HIV-1/2. Contrary to the trend seen at baseline, 
HIV-1 patients were generally older at ART initiation 
compared  with  HIV-2  patients.  Ten  (40%)  HIV-2 
patients had been started on a regimen of 3 NRTI and 
15 (60%) started on a regimen of 2NRTIs and 1 PI 
(Table II).
  The mean increase in CD4 for HIV-1 was 195, not 
statistically different from the one observed in HIV-2 
patients treated with a PI-based regimen at 6 and 12 
months (Fig.).
  The  immunological  results  obtained  with  a  PI-
based regimen were satisfactory both in naïve and non 
naïve patients. A slower but constant CD4 gain was 
observed in the patients with dual infection at 6 and 12 
months. In contrast, a decline in CD4 count was seen 
in the group of HIV-2 patients treated with 3 NRTIs. In 
view of this decline, these patients were all switched 
subsequently to a PI based regimen. Table I. Characteristics of individuals with HIV-1, HIV-2 and HIV-1/2 in MSF Khar Clinic (n=524)
Variable HIV-1
n (%)
HIV-2
n (%)
P valuea,b HIV-1&2
n (%)
P valuea,c
Total  489 (93) 28 (6) - 7 (1) -
Sex 
Females
Males 
Transgender
210 (43)
252 (51)
27 (6)
13 (46)
15 (54)
0
0.7
 -
2 (29)
5 (71)
0
0.7
-
Age (yr)
< 15
15-29
30-44
45+
36 (8)
96 (20)
293 (60)
64 (12)
1 (4)
1 (4)
14 (50)
12 (42)
0.6
0.03
0.29
<0.001
0 (0)
1 (14)
6 (86)
0 (0)
-
0.92
0.3
-
Age, yr, median (IQR) 33 (31-42) 44 (40-48)  <0.001 39 (31-43)  0.37
Marital status
Single
Married
Widowed
Divorced/separated
110 (22)
277 (57)
88 (18)
14 (3)
6 (21)
17 (61)
5 (18) 
0 (0)
0.9
0.7
0.9
-
1 (14)
4 (58)
2 (28)
0 (0)
0.9
0.7
0.8
-
Baseline CD4 cell count (cell/µl)
< 50 
50-199 
200-349 
≥350	
Median (IQR) (n=5161)
25 (5)
165 (34)
232 (47)
67 (14)
 221(76-307)
2 (7)
21 (75)
1 (4)
4 (14)
143 (73-144) 
0.93
<0.001
<0.001
0.8
0.08
0 )
6 (86)
1 (14)
0 
127 (91-160)
-
0.01
0.1
-
0.3
WHO clinical stage 
I 
II 
III
IV
151 (31)
83 (17)
183 (37)
72 (15)
0 (0)
4 (14)
11 (39)
13 (47)
-
0.9
0.8
<0.001
2 (29)
0 (0)
2 (29)
3 (43)
0.7
-
0.9
0.1
IQR, interquartile range; ART, antiretroviral therapy; WHO, World Health Organization; aχ² test for categorical variables and Wilcoxon rank-
sum test for continuous variables; bComparing HIV-1 with HIV- 2; cComparing HIV-1 with HIV-1 & 2
  Treatment outcomes censored at the end of June 
2009  included:  358  (81%)  alive  and  on  ART,  38 
(9%) deaths, 31 (7%) lost to follow up and 14 (3%) 
transferred out (Table II). 
Discussion
	 This	is	one	of	the	first	reports	describing	baseline	
characteristics and response to ART among patients 
with HIV-1, HIV-2 and dual HIV-1/2 in the routine 
setting  of  an  HIV  Clinic  in  Mumbai,  India.  Of 
particular	relevance	is	the	finding	that	HIV-2	and	dual	
infections are not uncommon, and it is likely that the 
situation is similar in other clinics in the same setting. 
It is necessary that the Ministry of Health along with 
partners works towards revision and adaptation of the 
current diagnostic and management protocols for HIV. 
What is urgently needed is to (i) include discriminatory 
testing and diagnosis of all HIV types; (ii) increase 
access  to  discriminatory  HIV-1  and  HIV-2  test  kits 
at  HIV  testing  sites.  Patients  found  to  have  dual 
infections should also have the possibility for access 
to	confirmatory	HIV	type-testing	at	identified	referral	
laboratories; and (iii)	provide	access	to	effective	first-
line ART regimens for both HIV-1, HIV-2 and dual 
infections in order to avoid the development of viral 
resistance  that  will  compromise  future  therapeutic 
options particularly for HIV-2. 
  Surprisingly  HIV-2  individuals  presented  with 
lower	CD4	counts	and	a	significantly	higher	proportion	
were  in  WHO  Clinical  Stage  4  when  compared  to 
HIV-1.	This	probably	reflects	delays	in	diagnosis	which	
can be due to a slower progression of the disease or to a 
lack of systematic screening for HIV-2. In the absence 
of discriminatory HIV testing, HIV-2 individuals might 
be  assumed  to  have  HIV-1  and  be  wrongly  placed 
on an ineffective ART regimen and progress in their 
illness before presenting to our clinic. Misdiagnosis 
686  INDIAN J MED RES, DECEMBER 2010of HIV-1/2 may also be a problem in many peripheral 
centres	in	Mumbai	and	accurate	identification	of	dual	
HIV-1/2  infection  remains  a  diagnostic  challenge. 
Although limited by sample size, two (50%) of the four 
patients with dual infections died during ART and this 
might be related to late diagnosis and ineffective initial 
ART regimens. This is suggested as both patients were 
non  naïve  and  had  very  low  baseline  CD4  counts. 
Discriminating between HIV-1 and HIV-2 is relatively 
simple as the rapid HIV detection assays (if available) 
are	 sensitive	 and	 specific	 for	 HIV-1	 and	 HIV-2.	
However,	these	assays	lack	specificity	for	dual	HIV-
1/2 infection. Different studies have shown that among 
individuals diagnosed as dual seropositive, often only 
HIV-1 or HIV-2 DNA is isolated (more often HIV-1), 
a  phenomenon  commonly  thought  to  be  explained 
by cross-reactivity17,30,31. However, this has important 
management implications and all patients found with 
dual	 infections	 should	 ideally	 undergo	 confirmatory	
testing using polymerase chain reaction techniques or 
Western blot. These are currently not available in the 
government ART centres. 
  Despite the fact that baseline CD4 cell counts at ART 
initiation were relatively similar between the different 
serotypes, CD4 cell recovery appeared to be poorer for 
dual infected patients than for HIV-1 and HIV-2, at 6 and 
at 12 months. The trend in CD4 gain in HIV-2 patients 
Table II. Characteristics and treatment outcomes of patients on ART (>6 months) according to HIV type in Khar Clinic (n=443)
Variable HIV-1a
n (%)
HIV-2
n (%)
P valueb, c  HIV-1&2
n (%)
P valueb,d
Total  414 25  - 4 -
Sex 
Females
Males 
TG
231 (56)
164 (40)
19 (4)
11 (44)
14 (66)
0
0.2
0.01
0 (0)
4 (100)
0
-
0.2
-
Age (yr)
<15
15-29
30-44
45+
18 (4)
78 (19)
274 (66)
44 (11)
0 (0)
15 (60)
10 (40)
-
<0.001
<0.01
0 (0)
4 (100)
0 (0)
Age, yr, median (IQR) 37 (33-43) 45 (41-49) 0.01 44 (39-43) 0.15
WHO clinical stage
Stage I or II (CD4<250 cells/µl)
Stage III
Stage IV
185 (45)
128 (31)
101 (21)
5 (20)
12 (48)
8 (32)
0.01
0.07
0.19
0 (0)
2 (50)
2 (50)
-
0.7
0.8
CD4 count, (cells/µl)
< 50 
50-199 
200-349 
≥350	
Median (IQR)
73 (18)
244 (59)
87 (21)
10 (2)
189 (72-262)
3 (12)
21 (84)
1 (4)
0 (0)
96 (73-111)
0.6
0.01
0.03
-
0.03
0 (0)
4 (100)
0 (0)
0 (0)
114 (79-150)
-
0.2
-
-
0.4
ART regimen 
2 NRTIs + 1 NNRTI
3 NRTIs
2 NRTIs + PIs
334 (81)
5 (1)
75 (18)
0 (0)
10 (40)
15 (60)
-
< 0.001
< 0.001
0 (0)
0 (0)
4 (100) 0.8
ART outcomes
Alive on ART
Dead
Lost to follow up
Transferred out
333 (80)
36 (9)
31 (8)
14 (3)
25 (100)
0 (0)
0 (0)
0 (0)
- 2 (50)
2 (50)
0 (0)
0 (0)
-
IQR, interquartile range; ART, antiretroviral therapy; WHO, World Health Organization; NRTI, nucleoside reverse transcriptase inhibitors; 
NFV,	nelfinavir;	LPV/r,	lopinavir/ritonavir;	IDV,	indinavir;	NNRTI,	non-nucleoside	reverse	transcriptase	inhibitors;	a 1unknown outcome for 
HIV-1; b x² test for categorical variables and Wilcoxon rank-sum test for continuous variables; c Comparing HIV-1 with HIV- 2; d Comparing 
HIV-1with HIV-1 & 2
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that all these patients were ART exposed (previously 
exposed to NNRTIs based regimens). The reason for this 
can be the systematic use of indinavir as the standard PI 
for HIV-2 in our setting22.
  The  failure  of  a  3NRTI  regimen  in  terms  of 
immunological  recovery  in  our  cohort  was  quite 
significant	and	highlights	the	need	to	review	treatment	
options for HIV-2 infection. Considering that all HIV-2 
patients who started 3 NRTIs were NNRTI naïve, the 
failure could be due to an infection with non-naïve 
virus (primary resistance), to undocumented previous 
exposure	 to	 double	 NRTIs	 (an	 ineffective	 first-line	
ART  regimen  containing  an  NNRTI)  or  due  to  an 
intrinsic incomplete suppression of viral loads on the 
triple NRTI regimen. This observation persuaded us to 
switch all the patients to a superior PI based regimen, 
and in future this will be the regimen of choice.
  The strengths of this study are that: (i) loss to follow 
up  was  relatively  low  (7%),  and  (ii)  the  data  came 
from	a	programme	setting	and	were	likely	to	reflect	
the operational reality on the ground. The limitations 
of the study included (i) limited number of patients 
and thus limited statistical power to detect statistically 
significant	differences,	(ii) a relatively short period of 
observation: the cohort thus needed to be followed up 
for a longer time period; and (iii) there were no data on 
viral load either at the start or during therapy. 
  In conclusion, in an HIV clinic in Mumbai, India, 
HIV-2 and dual infections are not uncommon and it is 
likely that the situation is similar in other clinics. An HIV 
testing strategy that discriminates between HIV types 
and	access	to	effective	first-line	ART	regimens	must	be	
considered to manage these patients effectively. 
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